Reports Q1 revenue $67.38M, consensus $63.67M. “We are pleased to report Q1 results that came in ahead of our expectations, reflecting both strong execution on our growth plan and improving industry dynamics,” said Melissa Tomkiel, Co-CEO and General Counsel. “Operationally, we’re making great progress optimizing how we deliver our end-to-end transplant service offering.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRTA:
- Strata Critical Medical management to meet virtually with Lake Street
- Cathie Wood Sells Strata Critical Medical (SRTA), but Top Analysts See 120% Upside in This Penny Stock. Here’s Why
- Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
- Cathie Wood’s $240M OpenAI Bet: ARK Adds OpenAI Exposure to ETFs Ahead of IPO
- Craig-Hallum bullish on Strata Critical Medical, initiates with a Buy